Company / Cost of Revenue
Tempest Therapeutics, Inc. Cost of Revenue History
FY2015-FY2017 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$2.2M
FY2017
5-year range
$0 / $2.2M
FY2015-FY2017
Trend
-
vs FY2016
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Increased from $0 to $2M over the past 2 years.
Based on SEC 10-K filings.
$2M in FY2017.
Increased from $0 to $2M over the past 2 years.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.69 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2017 | $2.2M | - |
| FY2016 | $0 | - |
| FY2015 | $0 | - |
As of FY2017 · SEC 10-K · Updated Jun 28, 2026